BioSpace News Archive

While there is much excitement about the arrival of the COVID-19 vaccine, there is also some skepticism with polls showing that up to 30 percent of Americans say they are not sure that they will get the vaccine.

Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Carl Morris, Ph.D., Chief Scientific Officer, will participate in a panel discussion at the virtual Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Day.

Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products is pleased to announce that Avicanna’s Chief Executive Officer, Aras Azadian has been invited to present at the Benzinga Biotech Small Cap Conference

Phase 2 study design based on successful Phase 1/2 trial including use of Tinnitus Functional Index (TFI) responder analysis for primary efficacy endpoint Patient enrollment criteria refined to enrich study population Top-line results expected in mid-2022

Prelude Corporation, a leader in molecular diagnostics and precision medicine for early stage breast cancer, announced that it has entered into an agreement with MultiPlan, Inc., the nation’s leading provider of healthcare cost management solutions to participate in MultiPlan’s primary and complementary networks.

Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), today announced financial results for the fourth quarter ended December 31, 2020 and provided an update on clinical and corporate developments.

Apnimed, a clinical-stage company focused on advancing pharmacologic treatments for sleep apnea and related disorders, announced today that it has raised $25 million in a Series B financing led by existing investor, Morningside Ventures, and joined by new investors, Seligman Investments and Tao Capital Partners.

Company affirms position as the largest wholesaler of branded products in the industry with $274.0 million in wholesale revenue for the year

– Dosed first patients in Phase 1 study with new product candidate A3907 – – First patient dosed in ASSERT global Phase 3 study of odevixibat for Alagille syndrome –

KM Biologics Co., Ltd. announced the results of the Phase I clinical study of a live attenuated tetravalent vaccine, KD-382*1, to prevent dengue*2.